ClariPulmo

ClariPi Inc.

ClariPulmo is an AI-powered tri-functional solution for lung CT images. Our deep learning model provides quantitative analysis of low-attenuation and high-attenuation lesions. In combination with ClariCTAI it reduces noise induced bias with 3D reporting.

Information source: Vendor
Last updated: October 4, 2023

General Information

General
Product name	ClariPulmo
Company	ClariPi Inc.
Subspeciality	Chest
Modality	CT
Disease targeted	COPD, emphysema, pneumonia, interstitial lung disease, COVID-19.
Key-features	Automatic segmentation and visualization of lungs and airways, LAA/HAA quantification, emphysema reporting
Suggested use	During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand), report suggestion

Technical Specifications

Data characteristics
Population	No restrictions
Input	CT, contrast or non-contrast
Input format	DICOM
Output	Volume rendering, automated report (two LAA and two HAA reports), heatmap overlay
Output format	DICOM SR
Technology
Integration	Integration in standard reading environment (PACS), Integration RIS (Radiological Information System), Integration CIS (Clinical Information System), Integration via AI marketplace or distribution platform, Stand-alone third party application
Deployment	Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based
Trigger for analysis	Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time	10 - 60 seconds

Regulatory

Certification
CE	Certified, Class IIa , MDD
FDA	510(k) cleared , Class II
Intended Use Statements
Intended use (according to CE)	ClariPulmo is a non-invasive image analysis software for use with CT images which is intended to aid the assessment of lung lesions (e.g., emphysema, pneumonia, etc). The software is designed to support the physician in confirming the presence or absence as well as quantification of physician identified lung lesions. The software will provide automated segmentation of the lungs and quantification of low-attenuation and high-attenuation areas within the segmented lungs by using predefined Hounsfield unit thresholds. The software displays by color the segmented lungs and identified lesions. ClariPulmo provides optional denoising and kernel normalization functions for an improved detection and quantification of lung lesions in cases when CT images were taken at low-dose conditions or with sharp reconstruction kernels.

Market

Market presence
On market since	03-2022
Distribution channels	Blackford, Eureka Clinical AI, deepcOS, CARPL.ai
Countries present (clinical, non-research use)	3
Paying clinical customers (institutes)	5
Research/test users (institutes)	3
Pricing
Pricing model	Pay-per-use, Subscription, One-time license fee
Based on	Number of installations, Number of analyses

Evidence

Evidence
Peer reviewed papers on performance	Emphysema quantification using low-dose computed tomography with deep learning–based kernel conversion comparison (read)
Non-peer reviewed papers on performance
Other relevant papers